In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • In my dark days I did not know how to explore trials for my husband. Cancer commons put me on the right path for all my options to explore. It is a load off my mind to know that I have some knowledge moving forward. Thank you for all your input!

    Cindy
    Wife of glioblastoma patient

  • Glioblastoma is devastating, and Cancer Commons made excellent recommendations to present to our medical team. They know what they are doing and have the experts that can sift through the voluminous mountain of research.

    Glory Cochrane
    Wife of glioblastoma patient

  • Now is the time to be very actively involved in your own care.

    Tony Blau, MD
    University of Washington

  • This free-of-charge, high-quality information service is a wonderful resource for patients with advanced cancer.

    Hope S. Rugo, MD
    UCSF Comprehensive Cancer Center

  • My contact was prompt, professional, and kind. Cancer Commons helped me review my options going forward.

    Cancer patient

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.